NVLN Logo.jpg
Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D
12. Oktober 2017 09:15 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
NVLN Logo.jpg
Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
05. Mai 2017 09:00 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
NVLN Logo.jpg
Novelion Therapeutics’ Subsidiary Launches JUXTAPID® (lomitapide) in Japan
16. Dezember 2016 08:35 ET | Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics (NASDAQ:NVLN) (TSX:NVLN), today announced that subsidiary Aegerion Pharmaceuticals completed the first...